Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2009-02-20
2011-12-27
Goddard, Laura B (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
08084583
ABSTRACT:
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6558669 (2003-05-01), Govindan et al.
patent: 6653104 (2003-11-01), Goldenberg et al.
patent: 6962702 (2005-11-01), Hansen et al.
patent: 7288249 (2007-10-01), Carter et al.
patent: 2003/0162709 (2003-08-01), Rossi et al.
patent: 10034607 (2002-02-01), None
patent: 98/12227 (1998-03-01), None
patent: 98/42378 (1998-10-01), None
patent: 00/69914 (2000-11-01), None
Ripani et al. Int. J. Cancer, 76(5):671-676, May 29, 1998.
Alberts et al. Molecular Biology of the Cell, 3rd Ed., pp. 1216-1218, Garland Publishing, Inc. (1994).
Basu et al. “The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303” Int. J. Cancer 62(4):472-479 (1995).
Bendig et al. “Humanization of Rodent Monoclonal Antibodies by CDR Grafting” Methods: A Companion to Methods in Enzymology 8:83-93-93 (1995).
Leung et al. “Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma” Hybridoma 13 (6):469-476 (1994).
Morrison et al. “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains” Proc. Natl. Acad. Sci, USA 81:6851-6855 (1984).
Paul, W. Fundamental Immunology, 3rd Ed., p. 242; pp. 292-295, Raven Press, New York (1993).
Qu et al. “Humanization of Immu31, an β-Fetoprotein-specific Antibody” Clin. Cancer Res. 5(10 Suppl):3094s-3100s (1999).
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity” Proc. Natl. Acad. Sci. USA 79:1979-1983 (1982).
Schoonjans et al. “FAB chains as an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives” J. Immunol. 165(12):7050-7057 (2000).
Shih et al.“The Processing and Fate of Antibodies and Their Radiolabels Bound to the Surface of Tumor Cells in Vitro: A Comparison of Nine Radiolabels” J. Nucl. Med. 35(5):899-908 (1994).
Shih et al. “In Vitro and in Vivo Reactivity of an Internalizing Antibody, RS7, with Human Breast Cancer” Cancer Res. 55(23 Suppl.):5857s-5863s (1995).
Stein et al. “Therapy of a Breast Cancer Xenograft Using Humanized RS7 Labeled with Residualizing Iodine” Proc. Am. Assoc. Cancer Res. vol. 43, pp. 88-89, Mar. 2002 (Abstract).
Stein et al. “Comparative Biodistribution and Radioimmunotherapy of Monoclonal Antibody RS7 and its F(ab')2 in Nude Mice Bearing Human Tumor Xenografts” Cancer 73:816-823 (1994).
Stein et al. “Effects of Radiolabeling Monoclonal Antibodies with a Residualizing Iodine Radiolabel on the Accretion of Radioisotope in Tumors” Cancer Res. 55(14):3132-3139 (1995).
Stein et al. “Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody” Int. J. Cancer 55(6):938-946 (1993).
Stein et al. “Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7” Int. J. Cancer 57(S8):98-102 (1994).
Stein et al. “Murine Monoclonal Antibodies Raised against Human Non-Small Cell Carcinoma of the Lung: Specificity and Tumor Targeting” Cancer Res. 50(4):1330-1336 (1990).
Goldenberg David M.
Govindan Serengulam V.
Hansen Hans J.
Qu Zhengxing
Goddard Laura B
Immunomedics Inc.
Nakashima Richard A.
Natarajan Meera
LandOfFree
RS7 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RS7 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RS7 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256298